# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, includi...
Proposed acquisition extends Organon's international dermatology capabilities to the U.S.Organon has agreed to acquire Derm...
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva,...
JP Morgan analyst Chris Schott downgrades Organon (NYSE:OGN) from Neutral to Underweight and raises the price target from $1...
Full year 2024 financial guidance is presented below on a non-GAAP basis, except revenue.Previous guidance as of May 2, 2024Cur...
Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot o...